Vidaza FDA Approval History
FDA Approved: Yes (First approved May 19, 2004)
Brand name: Vidaza
Generic name: azacitidine
Dosage form: for Injectable Suspension
Company: Pharmion Corporation
Treatment for: Myelodysplastic Diseases
Vidaza (azacitidine) is an antineoplastic agent for the treatment of patients with myelodysplastic syndromes.
Development timeline for Vidaza
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.